management hivaids normally includes use multiple antiretroviral drugs strategy control hiv several classes antiretroviral agents act different stages hiv lifecycle use multiple drugs act different viral targets known highly active antiretroviral therapy haart haart decreases patients total burden hiv maintains function immune system prevents opportunistic infections often lead haart also prevents transmission hiv serodiscordant samesex oppositesex partners long hivpositive partner maintains undetectable viral treatment successful many parts world hiv become chronic condition progression aids increasingly rare anthony fauci former head united states national institute allergy infectious diseases written collective resolute action steadfast commitment years come aidsfree generation indeed within reach paper noted estimated lives saved alone antiretroviral another commentary lancet noted rather dealing acute potentially lifethreatening complications clinicians confronted managing chronic disease absence cure persist many united states department health human services world health recommend offering antiretroviral treatment patients complexity selecting following regimen potential side effects importance taking medications regularly prevent viral resistance organizations emphasize importance involving patients therapy choices recommend analyzing risks potential defined health absence disease reason many researchers dedicated work better understanding effects hivrelated stigma barriers creates treatment interventions ways barriers six classes drugs usually used combination treat hiv infection antiretroviral arv drugs broadly classified phase retrovirus lifecycle drug inhibits typical combinations include two nucleoside reversetranscriptase inhibitors nrti backbone along one nonnucleoside reversetranscriptase inhibitor nnrti protease inhibitor pi integrase inhibitors also known integrase nuclear strand transfer inhibitors instis entry inhibitors fusion inhibitors interfere binding fusion entry host cell blocking one several targets maraviroc enfuvirtide ibalizumab available agents class maraviroc works targeting coreceptor located human helper tcells caution used administering drug however due possible shift tropism allows hiv target alternative coreceptor needed ibalizumab effective tropic hiv rare cases individuals may mutation delta gene results nonfunctional coreceptor turn means resistance slow progression disease however mentioned previously overcome hiv variant targets becomes prevent fusion virus host membrane enfuvirtide used enfuvirtide peptide drug must injected acts interacting nterminal heptad repeat hiv form inactive hetero sixhelix bundle therefore preventing infection host nucleoside reversetranscriptase inhibitors nrti nucleotide reversetranscriptase inhibitors ntrti nucleoside nucleotide analogues inhibit reverse transcription hiv rna virus integrated dna nucleus human cell unless first reverse transcribed dna since conversion rna dna naturally done mammalian cell performed viral protein reverse transcriptase makes selective target inhibition nrtis chain terminators nrtis incorporated dna chain lack oh group prevents subsequent incorporation nucleosides nrtis ntrtis act competitive substrate inhibitors examples nrtis include zidovudine abacavir lamivudine emtricitabine ntrtis tenofovir nonnucleoside reversetranscriptase inhibitors nnrti inhibit reverse transcriptase binding allosteric site enzyme nnrtis act noncompetitive inhibitors reverse transcriptase nnrtis affect handling substrate nucleotides reverse transcriptase binding near active site nnrtis classified generation generation nnrtis generation nnrtis include nevirapine efavirenz generation nnrtis etravirine intrinsically resistant integrase inhibitors also known integrase nuclear strand transfer inhibitors instis inhibit viral enzyme integrase responsible integration viral dna dna infected cell several integrase inhibitors clinical trialwhen raltegravir became first receive fda approval october raltegravir two metal binding groups compete substrate two ions metal binding site integrase early four clinically approved integrase inhibitors elvitegravir dolutegravir bictegravir protease inhibitors block viral protease enzyme necessary produce mature virions upon budding host membrane particularly drugs prevent cleavage gag gagpol precursor virus particles produced presence protease inhibitors defective mostly noninfectious examples hiv protease inhibitors lopinavir indinavir nelfinavir amprenavir ritonavir darunavir atazanavir recommended first line therapy maturation inhibitors similar effect binding gag development two experimental drugs class bevirimat vivecon halted resistance protease inhibitors high second generation drugs developed effective otherwise resistant hiv life cycle hiv short days viral entry cell replication assembly release additional viruses infection hiv lacks proofreading enzymes correct errors made converts rna dna via reverse transcription short lifecycle high error rate cause virus mutate rapidly resulting high genetic variability mutations either inferior parent virus often lacking ability reproduce convey advantage natural selection superiority parent enable slip past defenses human immune system antiretroviral drugs active copies virus greater possibility one resistant antiretroviral drugs antiretroviral drugs used improperly multidrug resistant strains become dominant genotypes rapidly era multiple drug classes available reversetranscriptase inhibitors zidovudine didanosine zalcitabine stavudine lamivudine used serially combination leading development multidrug resistant contrast antiretroviral combination therapy defends resistance creating multiple obstacles hiv replication keeps number viral copies low reduces possibility superior mutation conveys resistance one drugs arises drugs continue suppress reproduction mutation rare exceptions individual antiretroviral drug demonstrated suppress hiv infection long agents must taken combinations order lasting effect result standard care use combinations antiretroviral combinations usually consist three drugs least two different three drug combination commonly known triple combinations antiretrovirals subject positive negative synergies limits number useful combinationscitation needed hivs tendency mutate patients started antiretrovial regimen fail take regularly resistance hand patients take medications regularly stay one regimen without developing greatly increases life expectancy leaves drugs available individual need arisecitation needed recent yearswhen drug companies worked together combine complex regimens singlepill fixeddose antiretroviral fixeddose combinations developed greatly increases ease taken turn increases consistency medication taken thus effectiveness longterm although antiretroviral therapy helped improve quality life people living hiv still need explore ways address disease burden one potential strategy investigated add interleukin adjunct antiretroviral therapy adults hiv cochrane review included randomized controlled trials conducted across six researchers found interleukin increases immune cells make difference terms death incidence infections furthermore probably increase sideeffects interleukin findings review support use interleukin addon treatment antiretroviral therapy adults hivcitation needed antiretroviral drug treatment guidelines changed time antiretroviral drugs available treatment consisted treating complications opportunistic infections malignancies antiretroviral medications introduced clinicians agreed hiv positive patients low counts treated consensus formed whether treat patients high april merck national institute allergy infectious diseases began recruiting patients trial examining effects three drug combination protease inhibitor indinavir two nucleoside illustrating substantial benefit combining two nrtis new class antiretrovirals protease inhibitors namely indinavir later year david ho became advocate hit hard hit early approach aggressive treatment multiple antiretrovirals early course later reviews late early noted approach hit hard hit early ran significant risks increasing side effects development multidrug resistance approach largely abandoned consensus treating patients advanced immunosuppression counts less treatment antiretrovirals expensive time ranging timing start therapy continued core controversy within medical community though recentwhen studies led clarity study observed patients started antiretroviral therapy either count less versus less showed patients started art lower counts increase risk studies showed patients lived longer started antiretrovirals time diagnosis rather waiting counts drop specified level arguments starting therapy earlier people start therapy later shown less recovery immune higher counts associated less european medicines agency ema recommended granting marketing authorizations two new antiretroviral arv medicines rilpivirine rekambys cabotegravir vocabria used together treatment people human immunodeficiency virus type two medicines first arvs come longacting injectable means instead daily pills people receive intramuscular injections monthly every two combination rekambys vocabria injection intended maintenance treatment adults undetectable hiv levels blood viral load less copiesml current arv treatment virus developed resistance certain class antihiv medicines called nonnucleoside reverse transcriptase inhibitors nnrtis integrase strand transfer inhibitors separate argument starting antiretroviral therapy gained prominence effect hiv transmission art reduces amount virus blood genital shown lead dramatically reduced transmission hiv one partner suppressed viral load copiesml sex partner hiv negative clinical trial hptn serodiscordant heterosexual couples nine countries planned followed least years groups receiving education preventing hiv transmission condoms one group getting art study stopped early years ethical reasons became clear antiviral treatment provided significant protection couples crossinfection occurred one taken place control group consistent reduction risk transmission art single transmission experimental group occurred early starting art viral load likely preexposure prophylaxis prep provides hivnegative individuals conjunction safersex education regular hivsti order reduce risk acquiring journal science gave breakthrough year award treatment july consensus document created prevention access campaign endorsed organisations countries consensus document states risk hiv transmission person living hiv undetectable minimum six months negligible nonexistent negligible defined small unimportant worth considering chair british hiv association bhiva chloe orkin stated july doubt clear simple message person sustained undetectable levels hiv virus blood transmit hiv sexual furthermore partner ran enrolled serodiscordant couples one partner hiv positive negative study found estimated rate transmission condomless sex hivpositive partner taking art hiv load less copiesml summary hiv treatment guidelines state arv regimens available even poorest countries safer simpler effective affordable ever consensus among experts initiated antiretroviral therapy never stopped selection pressure incomplete suppression viral replication presence drug therapy causes drug sensitive strains selectively inhibited allows drug resistant strains become dominant turn makes harder treat infected individual well anyone else one trial showed higher rates opportunistic infections cancers heart attacks death patients periodically interrupted several treatment guidelines infected adults developed world countries access therapies laboratory tests united states international aids societyusa iasusa notforprofit organization well us governments department health human services europe european aids clinical society resource limited countries national guidelines closely follow world health organization guidelines use new criteria consider starting haart described however remain range views subject decision whether commence treatment ultimately rests patient doctorcitation needed us dhhs guidelines published april statecitation needed newest guidelines dated september agree baseline resistance presence resistance mutations patients never treated hiv countries high rate baseline resistance resistance testing recommended starting treatment initiation treatment urgent best guess treatment regimen started modified basis resistance uk medium highlevel resistance baseline combination efavirenz zidovudine lamivudine medium high level resistance stavudine lamivudine us one cohort patients never art least one resistance mutation various surveys different parts world shown increasing stable rates baseline resistance era effective hiv therapy baseline resistance testing combination antiretrovirals likely effective customized patientcitation needed haart regimens consist three drugs two nrtis backbone pinnrtiinsti base initial regimens use firstline drugs high efficacy low sideeffect profile us dhhs preferred initial regimens adults adolescents united states april efavirenz nevirapine showed similar benefits combined nrti case protease inhibitor based regimens ritonavir used low doses inhibit cytochrome enzymes boost levels protease inhibitors rather direct antiviral effect boosting effect allows taken less frequently throughout cobicistat used elvitegravir similar effect direct antiviral effect preferred initial regimen adults adolescents june first six months infection hiv viral loads tend elevated people often symptomatic later latent phases hiv disease may special benefits starting antiretroviral therapy early acute phase including lowering viral setpoint baseline viral load reduce mutation rate virus reduce size viral reservoir see section viral spartac trial compared weeks art vs weeks vs treatment acute hiv infection found weeks treatment delayed time decline count cells per ml weeks kept viral loads significantly lower even treatment since viral loads usually high acute infection period carries estimated times higher risk treating acutely infected patients presumed could significant impact decreasing overall hiv transmission rates since lower viral loads associated lower risk transmission see section treatment prevention however overall benefit proven balanced risks hiv treatment therapy acute infection carries grade bii recommendation us hiv especially harmful infants children one study africa showing untreated children born hiv died age five years old risk disease death hiv starts approach young adults recommends treating children less years old starting children older stage disease dhhs guidelines complicated recommend starting children less months old children age antiretrovirals use complicated fact many children born mothers hiv given single dose nevirapine nnrti time birth prevent transmission fails lead nnrti also large study africa india found pi based regimen superior nnrti based regimen children less years never exposed nnrtis thus recommends pi based regimens children less recommends children less children years less years adolescents kilograms us dhhs guidelines similar include pi based options children years systematic review assessed effects safety abacavircontaining regimens firstline therapy children month years age compared regimens review included two trials two observational studies almost eleven thousand hiv infected children adolescents measured virologic suppression death adverse events authors found meaningful difference abacavircontaining regimens nrticontaining regimens evidence low moderate quality therefore likely future research may change findingscitation needed goals treatment pregnant women include benefits mother infected adults well prevention transmission child risk transmission mother child proportional plasma viral load mother untreated mothers viral load copiesml transmission risk risk viral loads copiesml less art mothers delivery mothers infants delivery recommended substantially reduce risk mode delivery also important planned caesarian section lower risk vaginal delivery emergency caesarian hiv also detected breast milk infected mothers transmitted breast balances low risk transmission breast feeding women art benefits breastfeeding diarrhea pneumonia malnutrition also strongly recommends breastfeeding infants receive prophylactic us dhhs recommends women hiv improvements hiv therapy several studies estimate patients treatment highincome countries expect normal life means higher proportion people living hiv older research ongoing unique aspects hiv infection older adult data older people hiv blunted response therapy likely achieve undetectable viral however studies seen difference response guidelines separate treatment recommendations older adults important take account older patients likely multiple nonhiv medications consider drug interactions potential hiv also increased rates hiv associated nonaids conditions hana heart disease liver disease dementia multifactorial complications hiv associated behaviors coinfections like hepatitis b hepatitis c human papilloma virus hpv well hiv many factors may contribute depression adults living hiv effects virus brain infections tumours antiretroviral drugs medical rates major depression higher people living hiv compared general population may negatively influence antiretroviral treatment systematic review cochrane researchers assessed whether giving antidepressants adults living hiv depression may improve ten trials eight done highincome countries participants included results indicated antidepressants may better improving depression compared placebo quality evidence low future research likely impact findingscitation needed several concerns antiretroviral regimens addressed initiating suppressing viral load undetectable levels copies per ml primary goal happen weeks starting combination viral load monitoring important predictor response treatment lack viral load suppression art termed virologic failure levels higher copies per ml considered virologic failure prompt testing potential viral research shown people undetectable viral load unable transmit virus condomless sex partner either gender swiss statement described chance transmission low multiple studies since shown mode sexual transmission impossible hivpositive person consistently undetectable viral load discovery led formation prevention access campaign uu undetectableuntransmittable public information approach gained widespread support amongst hivaidsrelated medical charitable research studies demonstrating uu effective strategy preventing hiv transmission serodiscordant couples long partner living hiv durably suppressed viral load opposites partner partner malemale heterosexual studies couples one partner hivpositive one partner hivnegative enrolled regular hiv testing completed total four studies couples enrolled four continents acts condomless sex reported zero phylogenetically linked transmissions hiv positive partner undetectable viral following uu consensus statement advocating use zero risk signed hundreds individuals organisations including us cdc british hiv association lancet medical importance final results partner study described medical director terrence higgins trust impossible overstate lead author alison rodger declared message undetectable viral load makes hiv untransmittable help end hiv pandemic preventing hiv authors summarised findings lancet results provide similar level evidence viral suppression hiv transmission risk gay men previously generated heterosexual couples suggest risk hiv transmission gay couples condomless sex hiv viral load suppressed effectively zero findings support message uu undetectable equals untransmittable campaign benefits early testing treatment result consistent conclusion presented anthony fauci director national institute allergy infectious diseases us national institutes health team viewpoint published journal american medical association uu effective hiv prevention method undetectable viral load cell counts another key measure immune status art counts rise cells per ml first year substantial fluctuation counts based time day concomitant one longterm study majority increase cell counts first two years starting art little increase afterwards study also found patients began art lower counts continued lower counts started higher viral suppression art achieved without corresponding increase counts termed immunologic nonresponse immunologic failure predictive worse outcomes consensus adjust therapy immunologic failure whether switching therapy beneficial dhhs guidelines recommend switching otherwise suppressive innate lymphoid cells ilc another class immune cell depleted hiv infection however art initiated depletion around days post infection ilc levels maintained cell counts typically replenish effective art ilcs depletion irreversible art initiated depletion despite suppression since one roles ilcs regulate immune response commensal bacteria maintain effective gut hypothesized irreversible depletion ilcs plays role weakened gut barrier hiv patients even successful patients persistently detectable viral loads taking art tests done investigate whether drug resistance commonly genotype sequenced compared databases hiv viral genotypes resistance profiles predict response resistance testing may improve virological outcomes treatment failures however lack evidence effectiveness testing done treatment extensive resistance phenotypic test patients virus range drug concentrations performed expensive take several weeks genotypes generally using information genotype phenotype regimen three drugs least two classes constructed highest probability suppressing virus regimen constructed recommended first line agents termed salvage therapy six drugs needed termed drug holidays structured treatment interruptions intentional discontinuations antiretroviral drug treatment mentioned randomized controlled studies structured treatment interruptions shown higher rates opportunistic infections cancers heart attacks death patients took drug exception postexposure prophylaxis pep treatment guidelines call interruption drug therapy class individual antiretroviral carries unique risks adverse side effects nrtis interfere mitochondrial dna synthesis lead high levels lactate lactic acidosis liver steatosis peripheral neuropathy myopathy firstline nrtis lamivudineemtrictabine tenofovir abacavir less likely cause mitochondrial mitochondrial haplogroupsmtdna non pathologic mutations inherited maternal line linked efficacy count following idiosyncratic toxicity mtdna haplogroup also well studied boeisteril et al nnrtis generally safe well tolerated main reason discontinuation efavirenz neuropsychiatric effects including suicidal ideation nevirapine cause severe hepatotoxicity especially women high protease inhibitors pis often given ritonavir strong inhibitor cytochrome enzymes leading numerous drugdrug interactions also associated lipodystrophy elevated triglycerides elevated risk heart integrase inhibitors instis among best tolerated antiretrovirals excellent short medium term outcomes given relatively new development less long term safety data associated increase creatinine kinase levels rarely people exposed hivpositive infectious bodily fluids either skin puncture contact mucous membranes contact damaged skin risk acquiring hiv pooled estimates give risk transmission puncture exposures mucous membrane exposures united states guidelines state feces nasal secretions saliva sputum sweat tears urine vomitus considered potentially infectious unless visibly given rare nature events rigorous study protective abilities antiretrovirals limited suggest taking antiretrovirals afterwards prevent unknown three medications better two sooner exposure art started better period become ineffective unknown us public health service guidelines recommending starting prophylaxis week also recommend treating duration four weeks based animal studies recommended regimen emtricitabine tenofovir raltegravir insti rationale regimen tolerable potent conveniently administered associated minimal drug people exposed hiv follow hiv testing weekscitation needed women hiv shown decreased fertility affect available reproductive cases woman hiv negative man hiv positive primary assisted reproductive method used prevent hiv transmission sperm washing followed intrauterine insemination iui vitro fertilization ivf preferably done man achieved undetectable plasma viral past cases hiv transmission hivnegative partner processed artificial large modern series followed couples man stable viral load semen samples tested cases hiv cases woman hiv positive man hiv negative usual method artificial appropriate treatment risk mothertochild infection reduced several buyers clubs sprang since combat hiv drug zidovudine azt nucleoside reversetranscriptase inhibitor nrti effective approved us fda fda bypassed stages review safety effectiveness order distribute drug subsequently several nrtis developed even combination unable suppress virus long periods time patients still inevitably distinguish early antiretroviral therapy art term highly active antiretroviral therapy haart introduced two sequential publications new england journal medicine hammer gulick illustrated substantial benefit combining two nrtis new class antiretrovirals protease inhibitors namely indinavir concept threedrug therapy quickly incorporated clinical practice rapidly showed impressive benefit decline rates aids death haart became widespread fixed dose combinations made available ease administration later term combination antiretroviral therapy cart gained favor physicians accurate name conveying patients misguided idea nature today multidrug highly effective regimens long since default art increasingly called simply art instead haart retronymic process linguistically comparable way words electronic computer digital computer first needed make useful distinctions computing technology later irrelevance distinction computer alone covers meaning thus computers digital art combination art however names haart cart reinforced thousands earlier mentions medical literature still regularly cited also remain usecitation needed people living hiv expect live nearly normal life span able achieve durable viral suppression combination antiretroviral therapy however requires lifelong medication still higher rates cardiovascular kidney liver neurologic prompted research towards cure hiv socalled berlin patient potentially cured hiv infection treatment since detectable achieved two bone marrow transplants replaced immune system donors cell surface receptor needed variants hiv enter bone marrow transplants carry significant risks including potential death attempted necessary treat blood cancer attempts replicate successful given risks expense rarity negative donors bone marrow transplant seen mainstream inspired research methods try block expression gene therapy procedure zincfinger nucleasebased gene knockout used phase trial humans led increase count decrease viral load antiretroviral attempt reproduce failed analysis failure showed gene therapy successfully treats cells leaving majority cells capable infected analysis found patients less cells infected reduced viral load gene therapy effective native cells remained main limitation must overcome treatment become berlin patient two additional patients hiv infection cancer reported traceable hiv virus successful stem cell transplants virologist annemarie wensing university medical center utrecht announced development presentation towards hiv cure however two patients still antiretroviral therapy case berlin patient therefore known whether two patients cured hiv infection cure might confirmed therapy stopped viral rebound march second patient referred london patient confirmed complete remission hiv like berlin patient london patient received bone marrow transplant donor mutation antiviral drugs since september indicating berlin patient alternative approaches aiming mimic one biological immunity hiv absence mutation gene conducted current research efforts efforts done introduction induced pluripotent stem cells disrupted gene editing main obstacle complete elimination hiv infection conventional antiretroviral therapy hiv able integrate dna host cells rest latent state antiretrovirals attack actively replicating hiv cells hiv lies dormant called viral reservoir one main sources thought central memory transitional memory reports cure hiv two presumably due fact treatment initiated within hours infection preventing hiv establishing deep work donewhen try activate reservoir cells replication virus forced latency attacked antiretrovirals host immune system targets include histone deacetylase hdac represses transcription inhibited lead increased cell activation hdac inhibitors valproic acid vorinostat used human trials preliminary results even latent virus deactivated thought vigorous immune response need induced clear remaining infected strategies include using cytokines restore cell counts well therapeutic vaccines prime immune one candidate vaccine tat oyi developed vaccine based hiv protein tat animal models shown generation neutralizing antibodies lower levels hiv hiv vaccine development active area research important tool managing global aids epidemic research vaccine hiv ongoing decades lasting success preventing rapid development though mrna vaccines deal pandemic may provide new path forwardcitation needed like virus causes hiv spike protein retroviruses like hiv spike protein formed two proteins expressed env gene viral envelope binds host cell receptor gains virus entry mrna vaccines mrna messenger rna contains instructions make spike protein mrna put lipidbased nanoparticles drug delivery key breakthrough optimizing efficiency efficacy vivo vaccine injected mrna enters cells joins ribosome ribosome translates mrna instructions spike protein immune system detects presence spike protein b cells type white blood cell begin develop antibodies actual virus later enter system external spike protein recognized memory b cells whose function memorize characteristics original antigen memory b cells produce antibodies hopefully destroying virus bind another cell repeat hiv life rna important differences retrovirus insert copy rna genome host dna making total eradication virus also highly mutable making challenge adaptive immune system develop response chronic infection adaptive immune system undergo reciprocal selective pressures leading evolutionary arms race broadly neutralizing antibodies bnabs shown attach env spike protein envelope regardless specific hiv bodes well vaccine development complicating matters though naive b b cells yet exposed antigen progenitors rare mutation events needed turn b cells bnabs also growing consensus effective hiv vaccine need create humoral antibodymediated immunity tcellmediated mrna vaccines advantages traditional vaccines may help deal challenges presented hiv virus mrna vaccine codes protein spike whole virus possibility reverse transcription virus copies genetic material host genome present another advantage compared traditional vaccines speed development mrna vaccines take months years means multipart sequential vaccine regime possiblecitation needed attempts elicit immune response triggers broadly neutralizing antibodies bnabs single vaccine dose unsuccessful multipart sequential mrna vaccine regime however might guide immune response right direction first shot triggers immune response correct naive b cells later vaccinations encourage development cells eventually turning memory b cells later plasma cells secrete broadly neutralizing antibodies essence sequential immunization approach represents attempt mimic env evolution would occur natural contrast traditional primeboost strategies immunogen used repeatedly vaccination sequential immunization approach relies series different immunogens goal eventually inducing phase clinical trial scripps research international aids vaccine initiative mrna vaccine showed percent participants desired initial priming immune response naive b positive result developing first shot vaccine sequence moderna partnering scripps international aids vaccine initiative followup phase clinical trial hiv mrna vaccine starting later directtoconsumer advertisements hiv drugs past criticized use healthy glamorous models rather typical people hivaids usually people present debilitating conditions illnesses result hivaids contrast featuring people unrealistically strenuous activities mountain proved offensive insensitive suffering people hiv positive us fda reprimanded multiple pharmaceutical manufacturers publishing adverts misleading advertisements harmed consumers implying unproven benefits failing disclose important information overall drug companies chose present drugs realistic way consequently harmed general publics ideascitation needed suggesting hiv would affect much suggested led people wanting get testedcitation needed fear hiv positive time particularly contracted hiv seen death sentence known cure example case freddie mercurycitation needed died aged aidsrelated pneumonia preamble world health organizations constitution defines health state complete physical mental social wellbeing merely absence disease living hiv today met challenges go beyond singular goal lowering viral load metaanalysis studying correlates hivstigma found individuals living higher stigma burden likely poorer physical mental insufficient social support delayed diagnosis due decreased frequency hiv testing knowledge risk reduction cited people living hiv plhiv lower health related quality life hrqol scores general stigma hiv often compounded stigma identifying lgbtq community stigma injecting drug user idu even though heterosexual sexual transmission accounts infections aids cited heavily stigmatized medical condition among infectious part consequence stigma toward plhiv belief seen responsible status less deserving study sharing whos definition health critiques target goal part larger strategy aims eliminate aids epidemic public health threat arguing go far enough ensuring holistic health study suggests maintenance hiv aids go beyond suppression viral load prevention opportunistic infection proposes adding fourth addressing new quality life target would focus specifically increasing quality life able suppress viral load undetectable levels along new metrics track progress toward study serves example shifting paradigm dynamics health care system heavily diseaseoriented humancentered though questions remain exactly humancentered method treatment looks like practice generally aims ask kind support medical support plhiv need cope eliminate hivrelated campaigns marketing aimed educating general public order reduce misplaced fears hiv contraction one also encouraged capacitybuilding guided development plhiv leadership roles goal greater representation population decision making structural legal intervention also proposed specifically referring legal interventions put place protections discrimination improve access employment side practitioner greater competence experience people living hiv encouraged alongside promotion environment nonjudgment psychosocial group interventions psychotherapy relaxation group support education may beneficial effects depression hiv positive successful treatment management hivaids affected plethora factors ranges successfully taking prescribed medications preventing opportunistic infection food access etc food insecurity condition households lack access adequate food limited money resources food insecurity global issue affect billions people yearly including living developed countriescitation needed food insecurity major public health disparity united states america significantly affects minority groups people living poverty line living one morbidity december approximately people living hivaids plwha nyc described living level poverty food insecurity reported nyc department health march access consistent food supply safe healthy important part treatment management hivaids plwha also greatly affected food inequities food deserts causes food insecure food insecurity cause malnutrition also negatively impact hiv treatment recovery opportunistic infections similarly plwha require additional calories nutritionally support require foods free contamination prevent immunocompromising food insecurity exacerbate progression hivaids prevent plwha consistently following prescribed regimen lead poor outcomescitation needed imperative food insecurity among plwha addressed rectified reduce health inequitycitation needed important recognized socioeconomic status access medical care geographic location public policy race ethnicity play pivotal role treatment management hivaids lack sufficient constant income limit options food treatment medications inferred among oppressed groups society marginalized may less inclined encouraged seek care assistance endeavors address food insecurity included hiv treatment programs may help improve health outcomes also focuses health equity among diagnosed much focuses medications access consistently safe nutritious foods one important facets ensuring plwha provided best possible care altering narratives hiv treatment support garnered reduce food insecurity health disparities mortality rates decrease people living hivaidscitation needed httpsenwikipediaorgwikimanagementofhivaids